Safety and clinical and biological responses during the first 6 months of treatment by leuprolide or triptorelin, 1-month sustained-release LHRH agonists, in patients with metastatic prostatic cancer;Tolérance et réponses clinique et biologique au cours des 6 premiers mois de traitement par la leuproréline ou la triptoréline, agonistes de la LHRH à libération prolongée sur 1 mois chez des patients présentant un cancer de la prostate métastasé

Progres en Urologie

Volumn 7, Issue 6, 1997, Pages 984-995

  Abbou, Claude Clément ^a   Lucas, Christel ^b   Leblanc, Véronique ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b Laboratoires Takeda   (France)

Author keywords

Leuprolide; LHRH analogue; Prostatic adenocarcinoma; Triptorelin

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; IMIDAZOLE DERIVATIVE; IMIDAZOLIDINE DERIVATIVE; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERANCE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METASTASIS; MIDDLE AGED; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DATA INTERPRETATION, STATISTICAL; DRUG TOLERANCE; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TIME FACTORS; TRIPTORELIN;

EID: 0031297367     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. ARAI Y., YOSHIKI T., YOSHIDA O. Pronostic significance of specific antigen in endocrine treatment for prostatic cancer. J. Urol., 1990, 144, 1415-1419.
2. BOCCON-GIBOD L. The prevention of LHRH induced disease flares in patients with metastatic carcinoma of the prostate. Prog. Clin. Biol. Res., 1990, 359, 125-129.
3. BONNEY R.C. Trends and developments in endocrine therapies for breast and prostate cancer. In : Scrip Reports. Ed. PJB Publications Ltd., 1995, 2, 5-10.
4. CRAWFORD E.D., NABORS W. Hormone therapy of advanced prostate cancer : where we stand today. Oncology, 1991, 5, 21-30.
5. DU PLESSIS D.J Castration plus nilutamide versus castration plus placebo in advanced prostate cancer. A review. Urology, 1991, 37, 20-24.
6. GREGOIRE J.P., MOISAN J., LABRECQUE M., CUSAN L., DIAMOND P. Validation d'une adaptation française de l'échelle internationale de cotation des symptômes prostatiques. Prog. Urol., 1996, 6, 240-249.
7. KIENLE E., LÜBBEN G. Efficacy and safety of leuprorelin acetate depot for prostate cancer. Urol. Int., 1996, 56, 23-30.
8. KOJIMA M., OHE H , WATANABE H. Kinetic analysis of prostatic volume in patients with stage D prostatic cancer treated with LHRH analogues in relation to prognosis. Br. J. Urol., 1995, 75, 492-497.
9. KOSAKU N., MATSUMOTO K., SHIMIZU T., SATOH J. Post-therapeutic acute renal failure in an advanced prostate cancer patient treated with LH-RH analogue : a case report Nishinihon. J. Urol., 1994, 56, 293-295
10. KUHN J.M., BILLEBAUD T., NAVRATIL H. et al Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl J Med., 1989, 321, 413-418.
11. Mc NEAL J.E., GLEASON D.F. Classification de Gleason des adénocarcinomes prostatiques. Ann. Pathol, 1991, 11, 163-168.
12. MALHER C. Is disease flare a problem? Cancer, 1993, 72, suppl , 3799-3802.
13. MATZKIN H., EBER P., TODD B., VAN DER ZWAAG R., SOLOWAY M.S. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer, 1992, 70, 2302-2309.
14. MATZKIN H., PERITO P.E., SOLOWAY M.S. Prognostic factors in metastatic prostate cancer. Cancer, 1993, 72, 3788-3792.
15. MIGLIARI R., SCARPA R.M., CAMPUS G., De LISA A., ZUCCA I , D-ATRI M., SERRA A , USAI E. Evaluation of efficacy and tolerability of nilutamide and buserelin in the treatment of advanced prostate cancer. Arch. Ital. Urol. Nefrol. Androl , 1991, 63, 147-153.
16. O'BRIEN A., HIBBERD M. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer. J. Intern. Med. Res., 1990, 18, 57-68.
17. PARTIN A.W., OESTERLING J.E. The clinical usefulness of prostate specific antigen : update 1994. J. Urol., 1994, 152, 1358-1368.
18. SCALETSCKY R., SMITH J.A. Disease flare with gonadotropin-relasing hormone (GnRH) analogues. Drug Safety, 1993, 8, 265-270.
19. SHIMIZU T., SHIBATA Y., UCHIDA T., SATOH J. Severe flare-up in a prostate cancer patient treated with luteinizing hormone-releasing hormone analogue depot. Acta Uro. Jpn., 1993, 39, 953-955.
20. STAMEY T.A., KABALIN J.N., FERRARI M., YANG N. Prostate specific antigen in diagnosis and treatment of adenocarcinoma of the prostate. IV. Antiandrogen treated patients. J. Urol., 1989, 141, 1088-1090.